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Abstract
Background: For a long time cancer cells are known for increased uptake of glucose and its metabolization through
glycolysis. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a key regulatory enzyme of this pathway and can
produce ATP through oxidative level of phosphorylation. Previously, we reported that GAPDH purified from a variety of
malignant tissues, but not from normal tissues, was strongly inactivated by a normal metabolite, methylglyoxal (MG).
Molecular mechanism behind MG mediated GAPDH inhibition in cancer cells is not well understood.
Methods: GAPDH was purified from Ehrlich ascites carcinoma (EAC) cells based on its enzymatic activity. GAPDH
associated proteins in EAC cells and 3-methylcholanthrene (3MC) induced mouse tumor tissue were detected by
mass spectrometry analysis and immunoprecipitation (IP) experiment, respectively. Interacting domains of GAPDH
and its associated proteins were assessed by in silico molecular docking analysis. Mechanism of MG mediated GAPDH
inactivation in cancer cells was evaluated by measuring enzyme activity, Circular dichroism (CD) spectroscopy, IP and
mass spectrometry analyses.
Result: Here, we report that GAPDH is associated with glucose-6-phosphate isomerase (GPI) and pyruvate kinase M2
(PKM2) in Ehrlich ascites carcinoma (EAC) cells and also in 3-methylcholanthrene (3MC) induced mouse tumor tissue.
Molecular docking analyses suggest C-terminal domain preference for the interaction between GAPDH and GPI.
However, both C and N termini of PKM2 might be interacting with the C terminal domain of GAPDH. Expression of
both PKM2 and GPI is increased in 3MC induced tumor compared with the normal tissue. In presence of 1 mM MG,
association of GAPDH with PKM2 or GPI is not perturbed, but the enzymatic activity of GAPDH is reduced to 26.8 ± 5 %
in 3MC induced tumor and 57.8 ± 2.3 % in EAC cells. Treatment of MG to purified GAPDH complex leads to glycation
at R399 residue of PKM2 only, and changes the secondary structure of the protein complex.
Conclusion: PKM2 may regulate the enzymatic activity of GAPDH. Increased enzymatic activity of GAPDH in tumor
cells may be attributed to its association with PKM2 and GPI. Association of GAPDH with PKM2 and GPI could be a
signature for cancer cells. Glycation at R399 of PKM2 and changes in the secondary structure of GAPDH complex could
be one of the mechanisms by which GAPDH activity is inhibited in tumor cells by MG.
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Background
An important characteristic of rapidly proliferating ma-
lignant cells is their capacity of high aerobic glycolysis.
Cancer cells display a high level of glucose uptake and
enhanced lactic acid production as compared to normal
cells, a phenomenon widely known as the Warburg effect
[1]. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH,
EC 1.2.1.12) is a highly conserved and important enzyme
for catalyzing the 6th step of glycolysis by conversion of
glyceraldehyde-3-phosphate (GAP) and inorganic phos-
phate (Pi) into 1, 3-bisphosphoglycerate (1, 3-BPG) in the
presence of NAD+. GAPDH has been shown to exhibit
a wide variety of cellular functions like apoptosis,
neurotransmission, phagocytosis, and vesicle fusion in
ER to Golgi transport etc., besides its role as a glycolytic
enzyme [2–6]. Interestingly, GAPDH can also translocate
to the nucleus. Induction of GAPDH translocation to nu-
cleus causes cell death in human SH-SY5Y neuroblastoma
and rat neonatal cardiomyocytes [7, 8] and lowering such
nuclear localization suppresses apoptosis in ovarian cancer
cells [9]. Recent studies have established enhanced expres-
sion of both mRNA and protein level of GAPDH in hu-
man lung cancer tissues, pancreatic adenocarcinomas, and
dunning rat prostate cancer cell lines compared with
normal tissues and cell lines [10–12]. High expression
of GAPDH has been correlated with upregulation of
cell cycle related genes that are involved in G2/M tran-
sition, M phase regulation, glycolytic genes, and down
regulation of gluconeogenesis in non-small cell lung
carcinoma [13].
GAPDH is a homotetrameric protein with molecular
mass of 145 kDa. Each identical subunit contains 333
residues with molecular mass of 35.9 kDa [14]. In con-
trast, Bagui et al. [15] and Patra et al. [16] showed that
GAPDH is a heterodimer consisting of two non identical
subunits approximately of 33 and 55 kDa when purified
from Ehrlich ascites carcinoma (EAC) cells, mouse sar-
coma tissue, and human leukemic leukocytes. Interest-
ingly, methylglyoxal (MG), a normal metabolite could
inactivate GAPDH activity in a wide variety of malignant
cells and tissues, whereas it has no effect on GAPDH
from normal sources [17]. However, the mechanism be-
hind MG mediated inhibition of GAPDH activity in can-
cer cells is unknown.
Here, we report for the first time that purified GAPDH
complex purified from EAC cells contains two distinct
55 kDa subunits associated with a 33 kDa subunit. We
identify these two 55 kDa subunits as two glycolytic
enzymes- one is GPI and another is PKM2. GAPDH
can interact with both of these enzymes in EAC cells as
well as in 3MC induced tumor tissue. We establish that
MG glycates R399 residue located in M2 insert of PKM2
and changes the secondary structure of the GAPDH
complex. This study indicates a different molecular
association of GAPDH and underscores the glycation
events by methylglyoxal in cancer cells.
Methods
Propagation of EAC cells
EAC cells were maintained and grown in the peritoneal
cavity of Swiss albino mice as described previously [18]
following the guidelines of the Institutional Animal Eth-
ics Committee of Indian Association for the Cultivation
of Science (IACS) and ARRIVE guideline for reporting
animal research. Guidelines were approved by the Institu-
tional Animal Ethics Committee of IACS. Approximately,
106 cells were diluted in 0.2 ml of sterile normal saline
(0.9 %) and were used for inoculums. The cells were
harvested after 10–15 days. Erythrocytes were removed
by washing with 0.45 % NaCl.
Mass spectrometry
GAPDH was purified from EAC cells based on its enzym-
atic activity which was checked after each step of purifica-
tion as described previously [15]. Purified GAPDH complex
from EAC cells was run on 7.5–15 % SDS-PAGE, and
bands were visualized by Coomassie blue stainining.
Bands were excised from the gel and processed for mass
spectrometry analysis separately. Briefly, after reduction,
alkylation, and digestion with In-Gel tryptic Digestion Kit
(Thermo Fisher Scientific, Waltham, MA, USA), the
resulting peptide mixture was spotted using α-cyano-4-
hydroxy cinnamic acid (5.0 mg/mL, Sigma) in 70 %
acetonitrile in 0.1 % TFA and analyzed by MALDI-
TOF/TOF (Applied Biosystem 4700, USA) mass spec-
trometer in reflector mode for protein identification by
peptide mass fingerprint [19]. The mass spectrum was
acquired using 4000 series explorer v3.5 software and
peak list was generated between 800 and 4000 Da with
a signal-to-noise ratio of 25. The searching parameters
used for identification of acquired peptide spectrum were
taxonomy: mouse; cleavage enzyme: trypsin; maximum
number of miss cleavage 1; mass tolerance 100 ppm;
peptide charge: +1; variable modification: oxidation of
methionine and carbamidomethylation of cysteine, partial
N-terminal acetylation, modification of glutamine as fixed
modification of peptides. Data was analysed using GPS ex-
plore v3.0 (TM) software. The combined MS and MS/MS
results were matched with the NCBInr, SWISS PORT and
MSDB databases using MASCOT software v2.1 in order
to identify the proteins. Proteins were identified on the
basis of significant MASCOT Mowse-score (p < 0.05
where p is the probability that the observed match in a
random event).
The quality and accuracy of the data were examined
by determination of false discovery rate (FDR) values
using Mascot software (Matrix Science, London, UK) as
previously reported [20]. Briefly, Mascot generic format
Das et al. BMC Cancer  (2016) 16:152 Page 2 of 12
(MGF) file of raw combined MALDI-TOF and MALDI-
TOF/TOF data were created using following parameters
(MS peak filter: Peak density filter: 65/200 Da; S/N: 10;
No of peaks: 200; Area: 50; MS/MS peak filter: Peak dens-
ity filter: 65/200 Da; S/N: 5; No of peaks: 200; Area: 20).
MGF files were submitted to Mascot website to calculate
the FDR values of respective proteins. To find out the
stable glycation product, we treated purified protein com-
plex with 1 mM MG for five days at room temperature
[21]. Samples were run on 7.5–15 % SDS-PAGE followed
by mass spectroscopy analysis.
Development of tumor in the hind leg of mice
All animal experiments were carried out after receiving
the approval of guidelines from the Institutional Animal
Ethics Committee. Guidelines were adhered to ARRIVE
for reporting animal research. Guidelines were approved
by the Institutional Animal Ethics Committee. Mouse
tumor was generated using a previously reported method
[22]. Chemical carcinogen, 3MC, (Sigma-Aldrich, St. Louis,
Missouri, USA) was injected intramuscularly into the left
hind leg of Swiss albino female mice for three times with
one week intervals. Each dose was 10 mg.kg−1 bodyweight
in 0.05 ml of olive oil. At 98–105 days, full grown tumor
was developed at the site of 3MC injection in left leg
whereas no tumor formation was visible in contra lateral
right leg.
Electrophoresis, immunoblot analysis and
immunoprecipitation
Mouse tissue and EAC cell extracts were prepared in
modified radio immunoprecipitation assay buffer (RIPA,
composed of 50 mM Tris ⁄ HCl of pH 8.0, 150 mM sodium
chloride, 1.0 % Nonidet P-40, 4 mM EDTA of pH 8.0) with
1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluor-
ide and 1 % protease inhibitor cocktails (Sigma-Aldrich) at
4 °C as previously reported [22, 23]. Briefly, mouse tissue
and EAC cell were homogenized in RIPA buffer and
centrifuged at 10, 000 g for 10 min. The supernatant
was fractionated by 8 % SDS-PAGE and then transferred
to polyvinylidene difluoride membranes. The membranes
were blocked in PBS containing 5 % BSA and 0.05 %
Tween-20 for 1 h, and incubated overnight at 40 C with
primary antibodies to GAPDH (1:4 000), GPI (1:4 000,
Santa Cruz Biotechnology Inc., CA, USA), PKM2(1:3 000;
Cell Signaling Technology, Danvers, MA, USA) or β-
tubulin (1:4 000; Sigma-Aldrich). The membranes were
then washed and incubated with horseradish peroxidase-
conjugated secondary antibodies against mouse or rabbit
IgG at room temperature for 2 h and developed with the
supersignal west femto reagent (Thermo Fisher Scientific).
Chemiluminescence signal was captured on Kodak film.
Relative band intensity was quantified by using ImageJ
software (NIH, Bethesda, MD, USA) after normalizing
band intensity with β-tubulin.
For immunoprecipitation, tissue supernatants were in-
cubated with specific primary antibodies for overnight at
4 °C. Primary antibodies were then pooled down by in-
cubating with protein G agarose for an additional 4 h at
4 °C. Immunocomplexes were then subjected to western
blot analysis as described previously. To detect GPI and
PKM2 in the immunoprecipitate by western blot analysis,
we used Veriblot IP (Abcam, Cambridge, UK) secondary
antibody which detects only primary antibody used for
western blot, but not for immunoprecipitation.
Enzymatic assay
Both EAC and mouse tissue extracts in RIPA buffer were
used for enzymatic assay. GAPDH activity was assayed in
Triethanolamine-HCl buffer, pH 8.5 as described previ-
ously [15]. Briefly, 1 ml of assay mixture contained 50 mM
triethanolamine buffer, 50 mM Na2HPO4 (Sigma-Aldrich),
0.2 mM EDTA, 0.5 mM NAD+ and 0.04 mM of D-
glyceraldehyde- 3-phosphate (Sigma-Aldrich). The reaction
was carried out by the addition of 5 μg extracts, and moni-
tored by recording absorbance of NADH at 340 nm at 30 s
intervals. Increase in the absorbance values remained al-
most linear for 3 min (ΔA: 0.025–0.040 min−1). One unit
of activity of GAPDH was defined as the amount of en-
zyme required to convert 1 μmol of NAD+ to NADH per
min under standard assay conditions. The specific activity
was calculated as units of activity present per mg of pro-
tein. For MG mediated inhibition study, 30 μg of protein
from 3MC induced tumor tissue and EAC cell lysates were
preincubated with 0–1 mM MG for 10 min at 25 °C, and
enzymatic activity of GAPDH and GPI was measured. We
followed resorcinol method developed by Roe et al. [24] to
measure GPI activity. Briefly, resorcinol detects the keto
group present in fructose-6-phosphate. Samples from 3MC
induced tumors and EAC were incubated in 50 mM Tris ⁄
HCl buffer of pH 7.4 with 1 mM of substrate glucose-6-
phosphate in presence and absence of MG at different con-
centration for 10 min. 1 g/100 ml resorcinol solution and
10 N HCl at 1:7 ratio were added to the reaction and kept
for 10 min at 80 °C. Absorbance at 520 nm of was re-
corded using Varioskan Flash Elisa Reader (Thermo Fisher
Scientific). Absorbance of MG alone was subtracted from
that of resorcinol-fructose condensation product. Percent
of GAPDH or GPI activity was calculated by considering
specific activity of untreated sample as 100.
Molecular in silico docking analysis
Three-dimensional (3D) structures of human GAPDH
(Protein Data Bank (PDB) code: 1U8F, chain O) [25],
PKM2 (PDB code: 1ZJH, chain A) and GPI (PDB code:
1JLH, chain A) [26] were collected from the PDB data-
base [27]. 3D co-ordinates of GAPDH - PKM2 and
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GAPDH - GPI were further utilized for blind docking ap-
proach using three different protein-protein docking pro-
grams, ClusPro [28, 29], PatchDock [30] and SwarmDock
[31], respectively. Top 30 docking solutions from each of
the program’s output were selected and were further
utilized to identify the interacting interface using the
PDBePISA server [32]. Residues involved in the docking
interface from each protein chain were identified using in-
house perl scripts. Domain involvement of a protein for a
docking complex is assigned if 60 % or more residues
from the N or C terminal domains are involved in forming
the interface. Frequency of hydrogen bonding, salt bridge
formation and change in free energy (ΔG) of interaction
were extracted from the interface features calculated by
the PDBePISA [32] program.
Results
PKM2 and GPI are associated with GAPDH in cancer cells
Previous report by Bagui et al. [15] suggested that, on
purification and molecular mass determination of GAPDH
of EAC cells, 55 kDa subunit is associated with 33 kDa
subunit of GAPDH. To characterize this unknown subunit,
we purified GAPDH from EAC cells, based on its enzym-
atic activity (Additional file 1: Figure S1A-B). Additional
file 1: Figure S1B shows that specific activity of GAPDH
reached approximately 475 units/mg of protein, after pass-
ing through DEAE-Sephacell column. Interestingly, when
the Sephacell column eluents were subjected to gradient
SDS-PAGE, three bands of different sizes of approximately
58, 55 and 33 kDa were visible with different intensities
(Fig. 1a). We quantified the band intensity using ImageJ
analysis and found that three polypeptides were co-purified
at a 2.44 : 4.35 : 17.21 molar ratio, respectively (Fig. 1b),
suggesting that two types of polypeptides are associated
with GAPDH at different amount in the purified protein
complex of EAC cells.
To characterize the subunits associated with GAPDH
during purification, we carried out MALDI-TOF/TOF
experiments followed by peptide mass fingerprint (PMF)
analysis of the three bands present in SDS-PAGE. Figure 1c
shows the significantly identified proteins- PKM2 (from
band 1), GPI (from band 2), and GAPDH (from band 3).
We also performed false discovery rate (FDR) analysis to
examine the quality and accuracy of the identified proteins.
FDR values indicate that three proteins were identified
with zero false positive identification. Sequences of trypsin
digested fragments of the three individual bands were
mapped with the NCBI database sequences of mouse
PKM2 (KPYM_MOUSE), GPI (G6PI_MOUSE), and
GAPDH (DEMSG). We found that sequence coverage
for PKM2, GPI, and GAPDH were 21 %, 45 %, and 24 %
respectively (Additional file 1: Figure S1C-E). A list of
proteins detected from individual band in denatured
condition is enlisted in Additional file 1: Table S1-3.
Detection of PKM2 and GPI by MALDI-TOF/TOF ana-
lysis prompted us to confirm these three proteins by
immunoblot analysis. Figure 1d shows the detection of
three glycolytic enzymes in the DEAE-Sephacell column
eluents using specific antibody against each of these en-
zymes. Note that the amount of each enzyme increases in
the eluents (lanes 3 and 4) compared with the crude ly-
sates (lanes 1 and 2). Taken together, these results suggest
that GAPDH isolated from EAC cells is associated with
two glycolytic enzymes, PKM2 and GPI.
Expression of PKM2 and GPI increases in tumor tissue
To address the question whether this interaction of
GAPDH with PKM2 and GPI occurs in other type of
cancer cells, we used an in vivo tumor model system, in
which tumor was developed in mice muscle by injecting
a carcinogen, 3MC. We, first, checked the expression
profile of these three glycolytic enzymes in 3MC induced
tumor tissue by immunoblot analysis, and compared
with that of the normal tissue from the contra lateral leg
of same mouse. We found that both PKM2 and GPI
were increased whereas GAPDH was reduced in the tumor
(lane 3 and 4) compared with the normal tissue (lane 1
and 2, Fig. 2a). We quantified the expression of each of the
enzyme and Fig. 2b shows that expression of GPI is higher
by 2.2 ± 0.45 fold whereas as that GAPDH is lower by
1.8 ± 0.22 in 3MC induced tumor compared with nor-
mal tissue. On the other hand, PKM2 was not detect-
able in normal tissue. Christofk et al. [25] have recently
shown that PKM2, but not PKM1 (another alternative
spliced isoform of PKM), is advantageous for tumor cell
growth and critical for tumorigenesis. We checked the
expression of PKM1 in 3MC induced tumor tissue.
Additional file 1: Figure S2 shows that PKM1 is detect-
able only in normal tissue but not in the 3MC induced
tumor tissue, suggesting that tumor tissue expresses
only PKM2.
Association of GAPDH with PKM2 and GPI in tumor
cell was validated by immunoprecipitation assay. We
immunoprecipitated GAPDH in normal and 3MC induced
tumor tissue lysates using antibody against GAPDH, and
the precipitate was further probed with antibodies against
PKM2, GPI, and GAPDH. In Fig. 3a (and Additional file 1:
Figure S3A-B), panels 1 and 2 show that both PKM2 and
GPI are detectable in the immunoprecipitate of GAPDH
antibody, but not of mouse IgG, in 3MC induced tumor
tissue (lane 2). Panel 3 (Fig. 3a) indicates that GAPDH is
immunoprecipitated specifically by GAPDH antibody, but
not by mouse IgG, suggesting that both PKM2 and GPI
are associated with GAPDH in tumor but not in normal
tissue.
Also, we immunoprecipitated PKM2 in 3MC induced
tumor tissue lysate, and probed with antibodies against
GAPDH and GPI. Figure 3b shows that only GAPDH
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(panel 3), but not GPI (panel 2), is detectable in the im-
munoprecipitate of PKM2, suggesting that PKM2 inter-
acts with GAPDH, but not with GPI. Furthermore,
PKM2 was undetectable in the immunoprecipitate of
GPI antibody in the 3MC induced tumor tissue lysate
(Fig. 3c, panel 1, lane 2), confirming that there was no
interaction between GPI and PKM2 in tumor cells. Mouse
or rabbit IgG was used as control antibody for immuno-
precipitation. Immunoblot with secondary antibody against
mouse or rabbit IgG but not primary antibody was used
as a loading control for immunoprecipitate samples.
Altogether these data suggest that tumor cells show in-
creased expression of PKM2 and GPI, and two types of
GAPDH association-one is GAPDH-GPI and another is
GAPDH-PKM2-exist in the 3MC induced tumor tissue.
C-terminal domain of GAPDH interacts with PKM2 and GPI
In the preceding section, we have shown that GAPDH
can interact with GPI and PKM2 in cancer cells. In
order to assess which domain (s) of GAPDH, PKM2 and
GPI are involved in interaction; we carried out in silico
molecular docking analysis. 3D structure of human
Fig. 1 GAPDH is associated with PKM2 and GPI. a A representative of coomassie blue stained 7.5–15 % Tris-glycine SDS-PAGE gel of 10 μg purified
protein complex (PPC) from EAC cells. Three major bands with different molecular weight approximately 58, 55, 33 kDa are labeled with 1, 2,
and 3, respectively. b Mole of a subunit in the complex was calculated using a formula = [{(intensity of the band/total intensity of three bands)
x loading amount}/molecular mass]. Molar ratio is shown in pie chart. c Three bands were cut out from the gel for trypsin digestion followed
by MALDI-TOF/TOF analyses. Score of identified proteins from each band is tabulated. Note that bands 1, 2 and 3 contain mainly PKM2, GPI
and GAPDH respectively. Data from one representative experiment is shown here. Experiment was repeated six times. d Immunoblots of two
different amounts of crude extract and purified protein complex (PPC) from EAC cells with antibodies specific for PKM2 (panel 1), GPI (panel 2)
and GAPDH (panel 3). Note that both PKM2 and GPI were co-purified with GAPDH
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GAPDH (PDB code: 1U8F, chain O) was docked onto
PKM2 (PDB code: 1ZJH, chain A) and GPI (PDB code:
1JLH, chain A) independently without providing any
prior information to the docking programs. Top docking
solutions from each programs ClusPro [28, 29], Patch-
Dock [30] and SwarmDock [31] were screened and pooled
together for interface analysis. Figure 4 and Additional
file 1: Figure S4 plot the overall and average frequencies
of N or C terminal domain/residue involvement of
GAPDH, PKM2 and GPI proteins within the GAPDH-
PKM2 (Fig. 4 and Additional file 1: Figure S4A-C) and
GAPDH-GPI (Fig. 4 and Additional file 1: Figure S4D-F)
docking complexes, respectively. Frequencies of C terminal
domain of GAPDH are significantly higher in GAPDH-
PKM2 (Fig. 4b) and GAPDH-GPI (Fig. 4e) docking com-
plexes, advocating the role of C terminal part of GAPDH
in interaction with both PKM2 and GPI. Similarly, C ter-
minal domain of GPI (Fig. 4f) is more likely to be used in
interaction with GAPDH. However, in case of PKM2, it is
not quite evident which domain is more preferred to inter-
act with GAPDH despite of the slightly higher abundance
of C terminal domain at the interface (Fig. 4c).
Fig. 2 Expression profile of three enzymes in mouse normal and 3MC induced tumor tissues. a Lysates were subjected to immunoblot analysis
using anti-PKM2 (panel 1), −GPI (panel 2), −GAPDH (panel 3) and β-tubulin (panel 4) antibodies. β-tubulin was used as loading control for comparison
of GAPDH, PKM2 or GPI expression between normal (lane 1 and 2) and tumor (lane 3 and 4) tissues. Note that the expression level of PKM2 and GPI is
increased in tumor tissue. Purified protein complex (PPC) from EAC cells was considered as positive control for GAPDH, GPI, and PKM2 antibodies
(lane 5). b Quantification of band intensity of the immunoblot containing GPI and GAPDH. Fold induction in each case was calculated considering the
value relative band intensity for normal as “1”. Results are expressed as means ± SD from three independent experiments. **p < 0.01 for GPI or PKM2 in
tumor vs normal
Fig. 3 Both PKM2 and GPI interact with GAPDH. a Immunoprecipitate of GAPDH antibody was subjected to immunoblot with PKM2 (panel 1),
GPI (panel 2), GAPDH (panel 3) or mouse IgG heavy chain (panel 4) specific antibody. b Immunoprecipitate of PKM2 was subjected to immunoblot
with PKM2, GPI, GAPDH or rabbit IgG heavy chain specific antibody. c Immunoprecipitate of GPI was subjected to immunoblot with PKM2, GPI,
GAPDH or mouse IgG heavy chain specific antibody. Note that PKM2 was not immunoprecipitated with GPI antibody and vice versa. Mouse IgG was
used as negative control for immunoprecipitation of GAPDH and GPI antibodies, and rabbit IgG for PKM2 (lanes 3 and 4). Antibodies against heavy
chain of mouse IgG and rabbit IgG were used as loading controls for immunoblots (panel 4)
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Methylglyoxal can inhibit GAPDH activity in both EAC and
3MC induced tumor
Ray et al. [17] showed that MG inhibits the activity of
GAPDH of malignant cells but not of normal cells and
benign tumor cells. We found that GAPDH is associated
with two other glycolytic enzymes: PKM2 and GPI.
Whether PKM2 or GPI activity is affected by MG in
tumor cells, we measured the enzymatic activity of all
three enzymes in EAC and 3MC induced tumor tissue
in the presence of MG. Figure 5 shows that GPI activity
is less likely to be inhibited by 1 mM MG in 3MC in-
duced tumor (Fig. 5a) and EAC (Fig. 5b). In contrast,
GAPDH activity was reduced to 26.8 ± 5 % in the 3MC
induced tumor tissue (Fig. 5a) and to 57.8 ± 2 % in EAC
cell lysates (Fig. 5b) of total activity in the presence of
1 mM MG. We could not measure the effect of MG on
the activity of pyruvate kinase (PK) in tumor cells, which
may be explained due to very low activity of PK in
tumor cells [33]. Additional file 1: Figure S5A shows that
PK has 0.41 ± 0.12 U/mg and 1.55 ± 0.46 U/mg specific
activity in 3MC and EAC, respectively, compared with
12.2 ± 2.4 U/mg in normal tissue. We checked whether
MG has any influence on the interaction of these subunits
present in 3MC induced tumor in mouse. Additional
file 1: Figure S5B shows that both PKM2 and GPI are
detectable in the immunoprecipitate of GAPDH antibody
Fig. 4 Panel a provides the overall occurrence frequencies of C terminal, N terminal, and both NC of GAPDH and PKM2 proteins at the interface
observed within the 90 top scoring docking complexes obtained from three different programs whereas panels b (GAPDH) and c (PKM2) provides the
occurrence frequency of each residue within the GAPDH-PKM2 docking complexes. Panels d-f represent similar domain and residue occurrence
frequencies observed within the GAPDH-GPI docking complexes. An interface is regarded as C or N terminal interface if 60 % of the interface
residues for each protein reside within C or N termini, respectively
Fig. 5 MG inhibits GAPDH activity. Enzymatic activity of GPI and GAPDH in the extracts of 3MC induced tumor tissues (a) and EAC cells (b). Activity of
both enzymes was measured in the absence and presence of 0.5 and 1 mM MG at 25 °C for 10 mins. Percent inhibition was calculated considering
the activity of enzyme in absence of MG as 100 % (vehicle). Data presented as means ± SD from three independent experiments. **p < 0.01 vehicle vs
0.5 mM or 1 mM MG
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in the presence of 1 mM MG (lane 2). Whether the inacti-
vation by MG is due to conformational change of GAPDH
complex, we carried out circular dichroism (CD) spectros-
copy in the UV range with purified protein complex from
EAC cells. CD spectra of untreated GAPDH complexes
show two well minima at 208 and 222 nm, which are
characteristic of proteins containing α-helical secondary
structures. When these GAPDH complexes were treated
with MG the minima values at these two wave lengths de-
creased in a dose dependent manner (Additional file 1:
Figure S5C). We quantified the change of helicity in the
presence of MG, and Additional file 1: Figure S5D shows
that purified GAPDH complex exhibits 19 % and 20 %
change in the helicity in the presence of 1 mM MG for
6 h at 208 and 222 nm, respectively. Taken together, these
data suggest that MG may inhibit GAPDH activity by
changing the helicity of GAPDH complexes (with PKM2
or GPI) without interfering the interaction with them.
Methylglyoxal glycates M2 insert of PKM2 enzyme
It is known that MG can glycate arginine and lysine resi-
dues in proteins and produce methylglyoxal advanced
glycation end-products (MAGE) [19]. Using mass spec-
trometry analysis we checked if incubation by MG re-
sults in any glycation on arginine and lysine residues of
GAPDH complex. After incubation with 1 mM MG, bands
correspond to PKM2, GPI and GAPDH were analyzed.
Due to the mass increase characteristic of a MAGE, gly-
cated peptides had no match in the databases and were
therefore rejected [19]. This information can be used to
identify the molecular location of specific MAGE in target
protein(s). In the mass spectrometry of MG treated pro-
teins, several new peaks appear that do not have predicted
m⁄ z values. These new peaks may be due to the misclea-
vage of peptide(s). To know the mass of probable peptides
due to miscleavage, we performed a theoretical digestion
with the known protein sequence, considering upto four
trypsin miscleavages, cystine alkylation with iodoacetamide
and mono-isotopic peptide mass using Expasy website
[19]. With these theoretical peptide masses, the mass in-
crement due to a specific MAGE modification (54, 80 and
144 Da for arginine, 72 Da for lysine) were added to find
out if there were any new peaks which were matched with
the peak of mass spectrometry of MG treated proteins.
Using this approach, no such modified peptide peaks were
found in case of mass spectrometry of MG treated
GAPDH (except an unknown peak at m/z 2700.2021,
labeled with an arrow) or GPI compared with untreated
one (Additional file 1: Figure S6 A-B). Surprisingly,
when the mass spectrometry peaks of PKM2 were ana-
lyzed (Fig. 6), we found that one arginine residue was
modified by MG in the form of hydroimidazolone
(MG-H1) (red arrow, observed mass 2141.9580 Da, corre-
sponding to PKM2 peptide 384–400 with m/z 2087.9597
plus 54 Da of a MG-H modification). Detail glycated pep-
tide sequence which was obtained by comparing with the
theoretical data is shown in Additional file 1: Table S4.
Glycated peptide has miscleavage in Arg399 residue. In
contrast, no such peak with m/z value of 2141.9580 Da
was found in the untreated mass spectrometry. These data
suggest that MG can glycate Arg 399 in PKM2 of purified
GAPDH complex.
Previous report [34] revealed that the positively charged
residue R399 of PKM2 may play a critical role in forming
the PKM2 tetramer by a stable charge-charge interactions
with residues E418 and E396 of PKM2 which are located
on the other dimer of the tetramer PKM2. Replacing Ar-
ginine with Glutamic acid disrupts such interaction and
prefers dimmer, not tetramer. When R399 was mutated
with Alaline, mutant PKM2 was unable to translocate to
the nucleus in EGF mediated translocation, and unable to
interact with importin which facilitate nuclear transloca-
tion [35]. We assessed biochemical function of R399
residue of PKM2 using in silico molecular docking ana-
lysis at the interface with GAPDH. Figure 7a shows higher
abundance of Arginine 399 (R399) and its neighboring
residues (within 5 Å) at the interface with GAPDH.
Higher frequency of hydrogen bonding (Fig. 7b) and
salt bridge formation (Fig. 7c), while lower value of aver-
age ΔG of interaction (Fig. 7d) at the interface suggest the
importance of R399 and its neighboring residues in the
interaction with GAPDH.
Discussion
In this paper we demonstrate that association of GAPDH
with GPI or PKM2 exists in both EAC cells and 3MC
induced tumor tissue. MG can glycate PKM2 at R399
residue, which may induce structural changes in GAPDH
complex.
GAPDH was considered as a stable housekeeping marker
for constant gene expression [36]. However, recent times
have seen the ongoing discovery of new roles for GAPDH
in a diverse range of cellular processes which clearly dem-
onstrate that there are more complex roles of GAPDH in
case of cellular metabolism [37, 38]. Li et al. [39] reports
that GAPDH is physically associated with p300/CREB
binding protein associated factor (PCAF), and histone dea-
cetylase 5(HDAC5) for its higher enzymatic activity by
acetylation at active site’s lysine 254 residue in HEK 293 T
and A549 lung cancer cell line. GAPDH binds with SET
protein to regulate cyclin B-cdk1 activity [40]. However we
could not detect any association of these proteins with
GAPDH in the cells that we have used in our study. This
may be due to a different mechanism associated with post
translational modification based on regulation in gly-
colysis pathway in different cancer cells. Interestingly,
we could detect new peaks in the MG treated sample of
GAPDH, GPI and PKM2 that do not have predicted m/z
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values. One major peak was observed in case of treated
GAPDH at m/z value 2700 compared with untreated one
(Additional file 1: Figure S6A). But, the type of modifica-
tion is still unknown to us because this peak value does
not match with any theoretical peptide value after addition
of the mass increment due to MAGE modification. We
can not rule out the possibility of such modification in
GAPDH by MG, which may inhibit its enzymatic activity
Fig. 6 MG glycates M2 insert of PKM2 enzymes. Purified protein complex from EAC was treated with 1 mM MG for 5 days at room temperature.
MG treated or untreated samples were run on 7.5–15 % SDS-PAGE gel followed by mass spectroscopy analysis for PKM2. Area nearby glycated
peptide’s peak is magnified. Red arrow shows glycation at Arg 399 residue in M2 insert of PKM2 whereas black arrow for nonglycation of the
peptide of 17 aa
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in cancer cells. Further studies are being carrying out in
the laboratory to decipher the kind of modification oc-
curred in the presence of MG.
Pyruvate kinase of muscle cells (PKM) exist in two
isoforms: PKM1 and PKM2. They are generated due to
alternative splicing [41]. PKM2 regulates many meta-
bolic pathways for cancer cell survival and proliferation
[34, 42–45]. PKM2 activity supports Warburg effect for can-
cer cell survival [35, 46]. We checked the expression profile
of PKM isoforms in normal and 3MC induced-tumor tissues.
Interestingly, PKM2 was detectable in 3MC induced tumor
whereas PKM1 in normal tissue (Fig. 2a and Additional
file 1: Figure S2). MG could glycate Arg399, which is lo-
cated in alternatively spliced M2 insert of PKM2 of
purified GAPDH complex. These observations led us to
hypothesize that alternative splicing of PKM gene is an
important factor for association of GAPDH with PKM2,
which could be one of the ways for cancer cells to increase
high glycolytic activity. Glycation at Arg399 of PKM2
followed by conformational changes of the GAPDH
complexes could be one of the possible mechanisms for
MG mediated inhibition of glycolysis in tumor cells.
Recently, glycolytic enzyme, GPI has been shown to
regulate tumor cell growth and metastasis. Down regula-
tion of GPI increases sensitivity towards oxidative stress
and oxidative stress induced senescence [47]. Funasaka
et al. [48] have shown that hypoxia increases GPI ex-
pression in human breast carcinoma BT-549 cells. Inhib-
ition of GPI expression by siRNA reduces hypoxia induced
cancer cell motility. Association of GAPDH with PKM2
and GPI may give a special advantage for cancer cell me-
tabolism and survival. This association could be a signature
for cancer cells. Further studies are needed to understand
how interaction of GPI and PKM2 alters the activity of
Fig. 7 Panel a provides the distribution of occurrence frequencies of all residues (ALL), Arginine 399 (R399) and the residues within 5 Å distance
of R399 (R399_5A) of PKM2 protein. Panel b, c, and d provide similar distribution of hydrogen bonding, salt bridge, and average ΔG of interaction,
respectively
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GAPDH, and helps cancer cell metabolism for developing
a therapeutic approach for treatment of cancers.
Conclusion
GAPDH interacts with an alternatively spliced isoforms
of pyruvate kinase, PKM2 and GPI in cancer cells. These
interactions may be one of the reasons for cancer cells
to exhibit high glycolytic activity. MG can glycate at
R399 residue, located in M2 insert, of PKM2 and in-
hibits the GAPDH activity. This could be one of the
reasons for MG mediated inhibition of glycolysis in
cancer cells.
Additional file
Additional file 1: Supplementary material. (DOC 108 kb)
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